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Summary
Objectives: Mycobacterium peregrinum is a species included in the Mycobacterium fortuitum
complex, a member of the group of rapidly growing non-tuberculous mycobacteria (RGM). Only a
few cases of infection with M. peregrinum have been reported, and no relevant review has been
published.
Methods: Following the treatment of a patient with M. peregrinum infection after plastic
surgery, we undertook a review of the literature of previously reported cases of M. peregrinum
infection.
Results: Ten previously reported cases were identified. Like other cases of the M. fortuitum
complex infections, the majority of M. peregrinum infections were related to surgical site
infections and catheter-related infections. In the literature, most of the antibiotic regimens were
based on a combination of quinolones with various antibiotics, and the duration of treatment
ranged from 6 weeks to 4 months.
Conclusion: The fact that the optimal treatment for M. peregrinum infection has not yet been
established has resulted in the use of a diverse range of therapies. It is important that clinicians
carefully review each case so that amore appropriate treatment forM. peregrinum infections can
be determined.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +81 75 751 4967.
E-mail address: mnagao@kuhp.kyoto-u.ac.jp (M. Nagao).
1201-9712/$36.00 # 2008 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2008.06.018Introduction
Mycobacterium peregrinum is a species included in the
Mycobacterium fortuitum complex, a member of the group
of rapidly growing non-tuberculous mycobacteria (RGM).Published by Elsevier Ltd. All rights reserved.
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210 M. Nagao et al.Members of the M. fortuitum complex are ubiquitous in
nature and have been isolated in soil and various water-
related sources, including municipal tap water and hospital
water systems.1,2 Recently, the number of non-tuberculous
mycobacterium infection cases reported has been on the
rise, and the clinical importance of these organisms is grow-
ing.3—5 We report here a case of surgical site infection by M.
peregrinum. This should alert clinicians to the fact that M.
peregrinum may be the culprit of skin and soft tissue infec-
tions, especially after plastic surgery.
The case
A 58-year-old female underwent a surgical resection of a
13 cm  13 cm lipoma on her right chest wall. Her chest wall
and lower ribs were reconstructed using 30 cm  20 cm arti-
ficial sheets and artificial plates. Seven weeks after the
procedure, the patient developed pain and swelling of the
chest wall followed by a serious discharge running off via a
fistula on her chest wall, 5 cm below the operative scar. She
was immediately admitted to our hospital with a diagnosis of
surgical site infection. Empirical therapy with cefazolin was
begun at the time of admission. The discharge was submitted
for Gram stain and routine bacteriology, which were unre-
vealing. However, acid-fast staining was positive for numer-
ous mycobacteria. A mycobacterium was cultured at 7 days
and identified as M. peregrinum by DNA—DNA hybridization.6
M. peregrinum was obtained repeatedly from subsequent
exudates. Susceptibility testing by the broth microdilution
method complying with the guidelines of the Clinical and
Laboratory Standards Institute was undertaken, which
revealed sensitivity to amikacin (minimum inhibitory con-
centration (MIC) = 1), imipenem (MIC = 4), and levofloxacin
(MIC = 0.125) and resistance to clarithromycin (MIC > 32) and
doxycycline (MIC > 256).7 According to the susceptibility
testing, parenteral amikacin and imipenem were started
and the implant was removed followed by vigorous surgical
debridement. Ziehl—Neelsen stain of the debrided tissue was
positive for acid-fast bacilli, however the Gram stain was
negative. Histological examination of the tissue showed
many foreign body giant cells and neutrophils, yet caseous
necrosis and Langhans cells were not apparent. The post-
operative course was uneventful and imipenem was substi-
tuted for oral levofloxacin a week later. Antibiotics were
discontinued within 4 weeks postoperatively. The patient
remained well without further complication 6 months later.
Discussion
M. peregrinum is a rare organism isolated in only 1—2% of
RGM infections.8 Currently, there is no published series or
review evaluating the clinical significance of M. peregrinum,
and it is unclear whether M. peregrinum infection causes a
similar kind of infection to that found in our case. Using the
MEDLINE database with the keywords ‘Mycobacterium pere-
grinum’ and a bibliographic review of relevant clinical arti-
cles, we searched the literature for reports referring to M.
peregrinum. Only a small number of cases of sporadic infec-
tion have been reported; these are shown in Table 1.9—18
Hence, a total of 11 cases including the patient in our series
have been reported. These include four cases of skin and soft
Surgical site infection due to Mycobacterium peregrinum 211tissue diseases,9—11,18 two cases of medical device-related
infection,13,15 and one case of peritonitis.12 Like other mem-
bers of the M. fortuitum complex, the majority of M. per-
egrinum infections are related to surgical site infections and
catheter-related infections.8,19,20 M. peregrinum has also
been reported to cause a primary bacteremia, pneumonia,
and tonsillar abscess in immunosuppressed patients.15,17,18
The M. fortuitum complex is more sensitive than other
RGM,hence treatmentof these infections is generally easy and
effective.8,19,20 We determined an antibiotic regimen for our
patient using the current recommendations found in the
review ofM. fortuitum infection and by susceptibility testing,
which proved to be effective. In the literature cases, anti-
biotics were selected in reference with susceptibility testing
undertaken using the E-test and brothmicrodilution methods.
A combination of quinolones with various antibiotics was used
in many of the cases, and the duration of treatment ranged
from6weeks to 4months. The fact that the optimal treatment
for M. peregrinum infection has not yet been established has
resulted in the use of a diverse range of therapies.8,19,20 In our
case, the organism was resistant to clarithromycin and min-
ocycline, to which 80% and 46% of the M. fortuitum complex
have been reported to be resistant; thus imipenem and ami-
kacin were chosen. Although it has been reported that RGM
have a distinctive antimicrobial susceptibility profile depend-
ing on the species, susceptibility testing should be performed
for each strain. In the review of RGM cases, the reported
optimal duration of antibiotic therapy in skin and soft tissue
infections due to M. fortuitum ranged from 6 weeks to 4
months, depending on the study. In our case, therapy lasted
5 weeks. This shorter duration of antibiotic therapy was
sufficient, mainly because a complete resection of the
infected tissue was performed and the lesion was localized.
It is important that clinicians make an accurate diagnosis
and carefully review each case so that a more appropriate
treatment for M. peregrinum infections can be determined.
A case such as ours reminds us that a healthy suspicion for
unusual pathogens, such as the atypical mycobacteria, is
necessary when considering late-onset postoperative infec-
tion.
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